Thus, changes in EF1G levels have been pointed out in metastatic colon cancer and hepatic HepaG2 cells or cervical cancer specimens from patients in treatment with antineoplastic drugs (reviewed in [119]), while inhibition of IF4A1 may partially inhibit hepatocellular carcinoma progression [120]. Here, EEF1G is linked to cervical cancer.